Carbohydrate antigen 125 (CA125) following acute myocardial infarction: effects of empagliflozin and association with heart failure readouts in the EMMY trial
Journal: Scientific Reports
Year: 2025

Carbohydrate antigen 125 (CA125) is increasingly recognized as a biomarker in heart failure (HF). However, its response to sodium-glucose co-transporter 2 inhibitors (SGLT2i) after acute myocardial infarction (AMI) remains insufficiently explored. In this study, CA125 levels were measured from plasma samples collected in the EMMY trial, and robust linear mixed-effects models (R-LMEMs) were applied to assess the effects of empagliflozin on CA125 levels, their changes over a 26-week period, and th